Drug Profile
Research programme: therapeutic cancer vaccines - NCI/Intensity Therapeutics
Alternative Names: INT 223-8Latest Information Update: 28 Jun 2018
Price :
$50
*
At a glance
- Originator Intensity Therapeutics
- Developer Intensity Therapeutics; National Cancer Institute (USA)
- Class Cancer vaccines; Platinum complexes
- Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors; Immunostimulants; Natural killer cell receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2018 No recent reports of development identified for preclinical development in Cancer in USA (Intratumoural, Injection)
- 15 Jun 2017 Intensity Therapeutics has patents pending for its cancer vaccines in Australia
- 15 Jun 2017 Intensity Therapeutics receives patent allowance for its DfuseRxSM technology platform in USA